Cargando…
Tafenoquine at therapeutic concentrations does not prolong fridericia-corrected QT interval in healthy subjects
Tafenoquine is being developed for relapse prevention in Plasmodium vivax malaria. This Phase I, single-blind, randomized, placebo- and active-controlled parallel group study investigated whether tafenoquine at supratherapeutic and therapeutic concentrations prolonged cardiac repolarization in healt...
Autores principales: | Green, Justin A, Patel, Apurva K, Patel, Bela R, Hussaini, Azra, Harrell, Emma J, McDonald, Mirna J, Carter, Nick, Mohamed, Khadeeja, Duparc, Stephan, Miller, Ann K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BlackWell Publishing Ltd
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283056/ https://www.ncbi.nlm.nih.gov/pubmed/24700490 http://dx.doi.org/10.1002/jcph.302 |
Ejemplares similares
-
QT interval prolongation in opioid agonist treatment: analysis of continuous 12‐lead electrocardiogram recordings
por: Isbister, Geoffrey K., et al.
Publicado: (2017) -
High dose droperidol and QT prolongation: analysis of continuous 12-lead recordings
por: Calver, Leonie, et al.
Publicado: (2014) -
First-in-man safety and pharmacokinetics of synthetic ozonide OZ439 demonstrates an improved exposure profile relative to other peroxide antimalarials
por: Moehrle, Joerg J, et al.
Publicado: (2013) -
Tafenoquine succinate for malaria prevention
Publicado: (2019) -
Pharmacokinetic Interactions between Tafenoquine and Dihydroartemisinin-Piperaquine or Artemether-Lumefantrine in Healthy Adult Subjects
por: Green, Justin A., et al.
Publicado: (2016)